Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled time : 12:20 save search
Meiwu Technology Company Limited Regains Compliance with Nasdaq Minimum Bid Price Requirement
Published: 2022-10-28 (Crawled : 12:20) - globenewswire.com
WNW | $9.03 12441.67% 0.0% 0
|
|
| O: -1.2%
H: 3.3%
C: -3.94%
nasdaq technology
Loyalty Ventures Inc. Schedules Third Quarter 2022 Earnings Conference Call for November 8, 2022
Published: 2022-10-28 (Crawled : 12:20) - globenewswire.com
LYLT | $0.218 153.78% 60.41% 210M
|
|
| O: 15.04%
H: 3.85%
C: -11.54%
conference
LOYALTY VENTURES DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Loyalty Ventures To Contact Him Directly To Discuss Their Options
Published: 2023-05-13 (Crawled : 12:20) - prnewswire.com
LYLT | $0.218 153.78% 60.41% 210M
|
| Email alert
Add to watchlist
deadline
LOYALTY VENTURES SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Loyalty Ventures To Contact Him Directly To Discuss Their Options
Published: 2023-05-20 (Crawled : 12:20) - prnewswire.com
LYLT | $0.218 153.78% 60.41% 210M
|
| Email alert
Add to watchlist
LOYALTY VENTURES SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Loyalty Ventures To Contact Him Directly To Discuss Their Options
Published: 2023-06-24 (Crawled : 12:20) - prnewswire.com
LYLT | $0.218 153.78% 60.41% 210M
|
| Email alert
Add to watchlist
LOYALTY VENTURES SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Loyalty Ventures To Contact Him Directly To Discuss Their Options
Published: 2023-06-17 (Crawled : 12:20) - prnewswire.com
LYLT | $0.218 153.78% 60.41% 210M
|
| Email alert
Add to watchlist
LOYALTY VENTURES SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Loyalty Ventures To Contact Him Directly To Discuss Their Options
Published: 2023-05-06 (Crawled : 12:20) - prnewswire.com
LYLT | $0.218 153.78% 60.41% 210M
|
| Email alert
Add to watchlist
LOYALTY VENTURES SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Loyalty Ventures To Contact Him Directly To Discuss Their Options
Published: 2023-06-10 (Crawled : 12:20) - prnewswire.com
LYLT | $0.218 153.78% 60.41% 210M
|
| Email alert
Add to watchlist
LOYALTY VENTURES DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Loyalty Ventures To Contact Him Directly To Discuss Their Options
Published: 2023-06-03 (Crawled : 12:20) - prnewswire.com
LYLT | $0.218 153.78% 60.41% 210M
|
| Email alert
Add to watchlist
deadline
INVO Bioscience Announces Pricing of $3.0 Million Registered Direct Offering Priced At-The-Market
Published: 2023-03-24 (Crawled : 12:20) - prnewswire.com
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
|
| O: -7.35%
H: 4.16%
C: -1.46%
direct bioscience offering
TRACON Pharmaceuticals Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.K.
Published: 2022-04-19 (Crawled : 12:20) - globenewswire.com
TCON | $2.13 -6.99% -7.51% 350K
|
Health Technology
|
| O: 0.42%
H: 3.32%
C: 2.07%
TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference
Published: 2022-06-02 (Crawled : 12:20) - globenewswire.com
TCON | $2.13 -6.99% -7.51% 350K
|
Health Technology
|
| O: -2.94%
H: 0.0%
C: -3.03%
conference
Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2022-05-24 (Crawled : 12:20) - prnewswire.com
TCON | $2.13 -6.99% -7.51% 350K
|
Health Technology
|
| O: 1.1%
H: 2.19%
C: -1.64%
yh003 biopharma trials
TRACON to Report First Quarter 2022 Financial Results and Corporate Update on May 11, 2022
Published: 2022-05-04 (Crawled : 12:20) - globenewswire.com
TCON | $2.13 -6.99% -7.51% 350K
|
Health Technology
|
| O: -1.37%
H: 5.56%
C: 0.93%
report results
TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
Published: 2022-05-16 (Crawled : 12:20) - globenewswire.com
TCON | $2.13 -6.99% -7.51% 350K
|
Health Technology
|
| O: 2.41%
H: 17.59%
C: 13.53%
conference
TRACON to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 10, 2022
Published: 2022-07-27 (Crawled : 12:20) - globenewswire.com
TCON | $2.13 -6.99% -7.51% 350K
|
Health Technology
|
| O: 1.15%
H: 5.11%
C: 5.11%
report update results
TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial
Published: 2022-08-10 (Crawled : 12:20) - globenewswire.com
TCON | $2.13 -6.99% -7.51% 350K
|
Health Technology
|
| O: -0.53%
H: 14.97%
C: 10.7%
trial review results
TRACON Pharmaceuticals Announces Dosing of 36th Patient in ENVASARC Pivotal Trial Triggering Initial IDMC Efficacy Review Expected in the Fourth Quarter
Published: 2022-07-26 (Crawled : 12:20) - globenewswire.com
TCON | $2.13 -6.99% -7.51% 350K
|
Health Technology
|
| O: 1.16%
H: 2.29%
C: -0.57%
expected trial review
TRACON Pharmaceuticals Announces Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab
Published: 2022-08-29 (Crawled : 12:20) - globenewswire.com
TCON | $2.13 -6.99% -7.51% 350K
|
Health Technology
|
| O: 6.97%
H: 0.93%
C: -7.44%
yh001 treatment antibody approval
TWO ABSTRACTS AT AACR CONFERENCE PRESENT DETAILED STUDY DESIGN AND INNOVATIVE BIOMARKER STRATEGY FOR ONGOING PHASE I STUDY OF EVT801 IN ADVANCED CANCER
Published: 2022-04-08 (Crawled : 12:20) - prnewswire.com
KZIA | $0.3522 2.32% 2.27% 270K
|
Health Technology
|
| O: 4.2%
H: 1.42%
C: -0.59%
evt801 ongoing conference cancer designation biomarkers
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.